Reuters: Zimbabwe rolls out new HIV prevention drug lenacapavir
Zimbabwe’s health authorities on Thursday (19 February) began administering the long-acting injectable HIV prevention drug lenacapavir, making the country one of the first globally to roll it out as the southern African nation seeks to curb new infections. Health Minister Douglas Mombeshora said the programme, funded by the US and the Global Fund, would initially target more than 46,000 people at high risk of contracting HIV across 24 sites nationwide.
Kenya Ministry of Health: Kenya receives first shipment of long-acting HIV prevention drug lenacapavir
Kenya has received (17 February) an initial consignment of 21,000 starter doses of the long-acting injectable HIV prevention drug lenacapavir. The Ministry of Health will implement a phased, evidence-driven rollout guided by epidemiological trends and health-system readiness. Phase one, set to begin in March 2026, will target 15 high-burden counties, followed by two additional phases to progressively expand coverage nationwide, ensuring service preparedness, reliable commodity supply, and sustainable scale-up.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.